Effect of Trandolapril on Regression of Retinopathy in Hypertensive Patients with Type 2 Diabetes: A Prespecified Analysis of the Benedict Trial

Table 2

Concomitant medications in patients with type 2 diabetes and microalbuminuria at baseline and during follow-up according to treatment with ACE inhibitors YES or NO or with ndCCB YES or NO.

	Baseline				Follow-up
	ACEi Yes	ACEi No	ndCCB Yes	ndCCB No	ACEi Yes	ACEi No	ndCCB Yes	ndCCB No
Number of patients	42	48	50	40	39	44	47	36
Concomitant medication	number (percent)				number (percent)
Glucose-lowering regimen
Diet alone	5 (11.9)	12 (25.0)	12 (24.0)	5 (12.5)	4 (10.3)	8 (18.2)	8 (17.0)	4 (11.1)
Oral hypoglycemic agent  alone	29 (69.0)	21 (43.8)	26 (52.0)	24 (60.0)	24 (61.5)	21 (47.7)	26 (55.3)	19 (52.8)
Insulin and oral  hypoglycemic agent	5 (11.9)	12 (25.0)	10 (20.0)	7 (17.5)	11 (28.2)	16 (36.4)	13 (27.7)	14 (38.9)
Insulin alone	3 (7.1)	3 (6.3)	2 (4.0)	4 (10.0)	3 (7.7)	3 (6.8)	3 (6.4)	3 (8.3)
Antihypertensive agents
Any	22 (52.4)	26 (54.2)	23 (46.0)	25 (62.5)	32 (82.1)	38 (86.4)	37 (78.7)	33 (91.7)
Diuretic	5 (11.9)	11 (22.9)	9 (18.0)	7 (17.5)	10 (25.6)	14 (31.8)	16 (34.0)	8 (22.2)
Beta-blocker	6 (14.3)	2 (4.2)	3 (6.0)	5 (12.5)	4 (10.3)	3 (6.8)	4 (8.5)	3 (8.3)
Calcium-channel  blocker (dihydropyridine)	11 (26.2)	15 (31.3)	12 (24.0)	14 (35.0)	14 (35.9)	16 (36.4)	14 (29.8)	16 (44.4)
Sympatholytic agent	7 (16.7)	8 (16.7)	9 (18.0)	6 (15.0)	28 (71.8)	32 (72.7)	29 (61.7)	31 (86.1)
Lipid-lowering agents
Any	3 (7.1)	3 (6.3)	1 (2.0)	5 (12.5)	6 (15.4)	9 (20.5)	6 (12.8)	9 (25.0)
Statin alone	0	1 (2.1)	0	1 (2.5)	2 (5.1)	7 (15.9)	4 (8.5)	5 (13.9)
Fibrate alone	3 (7.1)	1 (2.1)	0	4 (10.0)*	2 (5.1)	0	1 (2.1)	1 (2.8)
Statin and fibrate	0	0	0	0	2 (5.1)	1 (2.3)	0	3 (8.3)
Antiplatelet agent	1 (2.4)	0	1 (2.0)	0	6 (15.4)	3 (6.8)	6 (12.8)	3 (8.3)

* $P<.05$ versus ndCCB YES.